Papillary Renal Cell Carcinoma Recruiting Phase 2 Trials for Sunitinib (DB01268)

IndicationStatusPhase
DBCOND0030667 (Papillary Renal Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03541902Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaTreatment